Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2016First federal award
$6.7MFederal grants as PI12 awards
1Patents grantedLatest Oct 2, 2018
126Papers9,632 citations
Federal awards and patents by year
AwardsPatents
12 awards · $6.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 9, 2024 | NIH | SBIR Phase I Therapy for Fecal Incontinence and FecalUrgency | $391K | Dignify Therapeutics LLC |
| Jun 2, 2022 | NIH | SBIR Phase II Pudendal neuromodulation for urinary and fecal incontinence and sphincter dyssynergia | $50K | Dignify Therapeutics LLC |
| Aug 31, 2021 | NIH | SBIR Phase II Pudendal neuromodulation for urinary and fecal incontinence and sphincter dyssynergia | $431K | Dignify Therapeutics LLC |
| Sep 22, 2020 | NIH | SBIR Phase II Pudendal neuromodulation for urinary and fecal incontinence and sphincter dyssynergia | $941K | Dignify Therapeutics LLC |
| Sep 24, 2019 | NIH | STTR Phase I Pudendal neuromodulation for incontinence and sphincter dyssynergia after spinal injury | $269K | Dignify Therapeutics LLC |
| Apr 2, 2019 | NIH | SBIR Phase II Development of a first-in-class therapeutic for producing 'on-demand' voiding | $999K | Dignify Therapeutics LLC |
| Jul 11, 2018 | NIH | SBIR Phase II An optimized NK2R agonist for 'on-demand' voiding | $615K | Dignify Therapeutics LLC |
| Jun 20, 2018 | NIH | SBIR Phase II Development of a first-in-class therapeutic for producing 'on-demand' voiding | $1.0M | Dignify Therapeutics LLC |
| Sep 8, 2017 | NIH | SBIR Phase II An optimized NK2R agonist for 'on-demand' voiding | $1.2M | Dignify Therapeutics LLC |
| Aug 22, 2017 | NIH | SBIR Phase I A neurokinin receptor agonist to treat underactive bladder in the elderly | $300K | Dignify Therapeutics LLC |
| Aug 7, 2017 | NIH | SBIR Phase II Development of a first-in-class therapeutic for producing 'on-demand' voiding | $300K | Dignify Therapeutics LLC |
| Sep 16, 2016 | NIH | SBIR Phase I Identification of an optimized NK2R agonist for 'on-demand' voiding | $276K | Dignify Therapeutics LLC |
2 patents as inventor
- US 10086034Dignify Therapeutics LLCOct 2, 2018
- US Dignify Therapeutics LLC—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#151
Awards as PI#86
Patents#155
Companies
- Dignify Therapeutics LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.